FAMEGLOW (08603) announced that the company has submitted an application for a transfer to the Main Board under Chapter 9B of the Listing Rules to the Stock Exchange on December 8, 2025. The transfer will not involve the issuance of any new shares by the company.

The Board believes that moving from the GEM to the Main Board will significantly enhance the company's corporate image and public recognition, given the Main Board's larger total market capitalization, higher trading volume, and relatively greater international visibility. As an established medical aesthetic service provider in Hong Kong, the Group views the stricter listing requirements and premium status associated with the Main Board as strong validation of its operational performance and market position.

This reputational boost is expected to strengthen the company's ability to attract and retain high-quality clients, business partners, and talent while facilitating more effective capture of new business opportunities. Additionally, the Board anticipates that a Main Board listing will broaden the company's access to a wider investor base, including institutional, professional, and international investors, thereby expanding and diversifying its shareholder structure.

The transfer is also projected to improve the company's financing flexibility, enabling it to secure more diversified debt financing options on more favorable terms. This will support capital structure optimization and provide greater strategic financial management capabilities.

The Board believes the transfer will positively contribute to the Group's sustainable growth and long-term development, reinforcing its leadership in the medical aesthetics sector and creating lasting value for the company and its shareholders.